The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Open accessAbstract
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset of patients are lean, but their underlying pathophysiology is not well understood. Approach and Results: We investigated the role of bile acids (BAs) and the gut microbiome in the pathogenesis of lean NAFLD. BA and fibroblast growth factor (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin‐like phospholipase domain containing 3 (PNPLA3), and transmembrane 6 superfamily member 2 (TM6SF2) variants, and gut microbiota profiles in lean and nonlean NAFLD were investigated in a cohort of Caucasian patients with biopsy‐proven NAFLD (n = 538), lean healthy controls (n = 30), and experimental murine models. Patients with lean NAFLD had a more favorable metabolic and histological profile compared with those with nonlean NAFLD (P < 0.05 for all). BA levels were significantly higher in NAFLD with advanced compared with earlier stages of liver fibrosis. Patients with lean NAFLD had higher serum secondary BA and FGF19 levels and reduced 7‐alpha‐hydroxy‐4‐cholesten‐3‐one (C4) levels (P < 0.05 for all). These differences were more profound in early compared with advanced stages of fibrosis (P < 0.05 for both). Lean patients demonstrated an altered gut microbiota profile. Similar findings were demonstrated in lean and nonlean murine models of NAFLD. Treating mice with an apical sodium‐dependent BA transporter inhibitor (SC‐435) resulted in marked increases in fgf15, a shift in the BA and microbiota profiles, and improved steatohepatitis in the lean model. Conclusions: Differences in metabolic adaptation between patients with lean and nonlean NAFLD, at least in part, explain the pathophysiology and provide options for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971 · cited 5×
“(15,16) The gut microbiome is also intimately involved in the pathogenesis of several metabolic diseases, including body weight regulation, NAFLD, and liver cancer, in part through direct interactions with BAs.”
BackgroundInfluentialThe metabolically obese, normal-weight individual revisited.
Ruderman, N., Chisholm, D., Pi-Sunyer, X., & Schneider, S. (1998) · Diabetes · doi:10.2337/diabetes.47.5.699 · Cited by 893
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis
Kakiyama, G., Pandak, W. M., Gillevet, P. M., Hylemon, P. B., Heuman, D. M., Daita, K., Takei, H., Muto, A., Nittono, H., Ridlon, J. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.003 · Cited by 781
Musso, G., Gambino, R., De Michieli, F., Cassader, M., Rizzetto, M., Durazzo, M., Fagà, E., Silli, B., & Pagano, G. (2003) · Hepatology · doi:10.1053/jhep.2003.50132 · Cited by 759
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Self-citationJiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314307 · Cited by 737 · cited 2×
“FXR dysregulation has been implicated in the pathogenesis of NAFLD; therefore, we were interested to determine if differential effects are observed in lean versus nonlean NAFLD.(20,21) To examine for this, serum FGF19, a surrogate marker of FXR activity, was measured.”
BackgroundDel Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
Min, H.-K., Kapoor, A., Fuchs, M., Mirshahi, F., Zhou, H., Maher, J., Kellum, J., Warnick, R., Contos, M. J., & Sanyal, A. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.004 · Cited by 652
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591 · cited 1×
“(32) Furthermore, in both humans and murine models, elevated BAs play a role in the metabolic improvements after bariatric surgery, including in type 2 diabetes, dyslipidemia, and NASH, even before significant weight loss.(33-35) Thus, we suggest that patients who are lean can adapt metabolically and excrete greater a…”
Fu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M., Williams, P. M., Soriano, R., Corpuz, R., Moffat, B., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1671 · Cited by 579
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet
Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., Yokoyama, M., Honda, M., Zen, Y., Nakanuma, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21874 · Cited by 515
Zhou, D., Pan, Q., Xin, F.-Z., Zhang, R.-N., He, C.-X., Chen, G.-Y., Liu, C., Chen, Y.-W., & Fan, J.-G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.60 · Cited by 441
The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity
Broeders, E. P. M., Nascimento, E. B. M., Havekes, B., Brans, B., Roumans, K. H. M., Tailleux, A., Schaart, G., Kouach, M., Charton, J., Deprez, B., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.002 · Cited by 439
Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426
The Role of the Gut Microbiota in Bile Acid Metabolism
Ramírez-Pérez, O., Cruz-Ramón, V., Chinchilla-López, P., & Méndez-Sánchez, N. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5672 · Cited by 391
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354 · cited 1×
“Alternatively, changes in microbiota might explain the development of steatosis.(37) Lean NAFLD had a distinct separation in microbiota profile compared with the healthy controls, with an increased abundance of Dorea that has been implicated in the pathogenesis and progression of NASH(38) and a decrease of several spe…”
BackgroundHepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis
Van Rooyen, D. M., Larter, C. Z., Haigh, W. G., Yeh, M. M., Ioannou, G., Kuver, R., Lee, S. P., Teoh, N. C., & Farrell, G. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.040 · Cited by 345
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2018) · Hepatology Communications · doi:10.1002/hep4.1124 · Cited by 309
Chambers, A. P., Jessen, L., Ryan, K. K., Sisley, S., Wilson–Pérez, H. E., Stefater, M. A., Gaitonde, S. G., Sorrell, J. E., Toure, M., Berger, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.050 · Cited by 289
Watanabe, M., Horai, Y., Houten, S. M., Morimoto, K., Sugizaki, T., Arita, E., Mataki, C., Sato, H., Tanigawara, Y., Schoonjans, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248203 · Cited by 254
Yasutake, K., Nakamuta, M., Shima, Y., Ohyama, A., Masuda, K., Haruta, N., Fujino, T., Aoyagi, Y., Fukuizumi, K., Yoshimoto, T., et al. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802588133 · Cited by 217
Martínez, I., Perdicaro, D. J., Brown, A. W., Hammons, S., Carden, T. J., Carr, T. P., Eskridge, K. M., & Walter, J. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.03046-12 · Cited by 215
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
Ma, J., Zhou, Q., & Li, H. (2017) · Nutrients · doi:10.3390/nu9101124 · Cited by 197
Ioannou, G. N., Morrow, O. B., Connole, M. L., & Lee, S. P. (2009) · Hepatology · doi:10.1002/hep.22941 · Cited by 168
Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype
Ding, C., Chan, Z., & Magkos, F. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000317 · Cited by 159
Zhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., Wang, N., & Lu, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00233 · Cited by 158
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease
Cruz, A. C. D., Bugianesi, E., George, J., Day, C. P., Liaquat, H., Charatcharoenwitthaya, P., Mills, P. R., Dam‐Larsen, S., Bjornsson, E. S., Hafliðadóttir, S., et al. (2014) · Gastroenterology · doi:10.1016/s0016-5085(14)63307-2 · Cited by 144
Self-citationHepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice
Fan, Y., Lu, H., Guo, Y., Zhu, T., Garcia-Barrio, M. T., Jiang, Z., Willer, C. J., Zhang, J., & Chen, Y. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.005 · Cited by 95
Pang, J., Xu, W., Zhang, X., Wong, G. L., Chan, A. W. H., Chan, H., Tse, C., Shu, S. S., Choi, P. C., Chan, H. L., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14119 · Cited by 94
Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol
Enjoji, M., Yasutake, K., Kohjima, M., & Nakamuta, M. (2012) · International Journal of Hepatology · doi:10.1155/2012/925807 · Cited by 87
Tu, L. N., Showalter, M. R., Čajka, T., Fan, S., Pillai, V. V., Fiehn, O., & Selvaraj, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-05040-6 · Cited by 87
An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers
Al-Khaifi, A., Rudling, M. J., & Angelin, B. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.038 · Cited by 65
Lean NASH: distinctiveness and clinical implication
Das, K., & Chowdhury, A. (2013) · Hepatology International · doi:10.1007/s12072-013-9477-5 · Cited by 64
Activation of bile acid signaling improves metabolic phenotypes in high-fat diet-induced obese mice.
Pierre, J., Martinez, K., Ye, H., Nadimpalli, A., Morton, T. C., Yang, J., Wang, Q., Patno, N., Chang, E., & Yin, D.-P. (2016) · American Journal of Physiology - Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00202.2016 · Cited by 64
Desmosterol in Human Nonalcoholic Steatohepatitis
Simonen, M., Männistö, V., Leppänen, J., Kamińska, D., Kärjä, V. J., Venesmaa, S., Käkelä, P., Kuusisto, J., Gylling, H., Laakso, M., et al. (2013) · Hepatology · doi:10.1002/hep.26342 · Cited by 59
Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
Kohli, R., Myronovych, A., Tan, B. K., Salazar-Gonzalez, R.-M., Miles, L., Zhang, W., Oehrle, M., Sandoval, D. A., Ryan, K. K., Seeley, R. J., et al. (2015) · Digestive Diseases · doi:10.1159/000371699 · Cited by 30
Klass, D. M., BÜHRMANN, K., Sauter, G. H., Puppo, M. D., Scheibner, J., Fuchs, M. A., & Stange, E. F. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02836.x · Cited by 22
Cited by
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationYe, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citationAnstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499
Self-citation
Metadata
- Authors
- Chen, F., Esmaili, S., Rogers, G. B., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M. K., Coulter, S., Choo, J. M., Younes, R., Rosso, C., Liddle, C., Adams, L. A., Craxì, A., George, J., & Eslam, M.
- Venue
- Hepatology
- Published
- 2020-01-24
- Volume
- 71
- Issue
- 4
- Pages
- 1213-1227
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2969841699
- Cited by
- 327
- References
- 44
- FWCI
- 27.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.